ICCC Q4 2025 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-1.6% YoY

Gross Profit

$3M38.2% margin

Operating Income

-$58,000-0.8% margin

Net Income

-$3M-37.4% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+38.5%

Balance Sheet

Total Assets

$43M

Total Liabilities

$0

Stockholders' Equity

$0

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$8M	-1.6%
Gross Profit	$3M	$3M	+2.8%
Operating Income	-$58,000	$621,395	-109.3%
Net Income	-$3M	$514,555	-653.7%